
Figure e-1. Incidence of (A) flushing and related symptoms^a and (B) GI events^b by yearly interval in ENDORSE.



^aFlushing and other related symptoms consist of the preferred terms of Flushing and Hot Flush, Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia under MedDra V13.1

ENDORSE Year 2

472

465

208

205

101

ENDORSE Year 3

430

195

189

88

096

TID/TID

PBO/BID

PBO/TID

GA/BID

GA/TID

Patients at risk: BID/BID

ENDORSE Year 1

501

501

249

248

118

^bGastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations' or 'Gastrointestinal nonspecific symptoms and therapeutic procedures' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions') under MedDra V13.1.

AE, adverse event; BID, twice daily; GA, glatiramer acetate; GI, gastrointestinal; PBO, placebo; TID, thrice daily.